Beta blockers hair loss is a recognised but often overlooked side effect of this widely prescribed class of medicines. Beta blockers are used to treat high blood pressure, heart failure, arrhythmias, angina, and anxiety, and whilst they are generally well tolerated, some patients notice increased hair shedding or thinning during treatment. Listed in several UK Summaries of Product Characteristics (SmPCs), this side effect is thought to involve premature disruption of the hair growth cycle. This article explains the mechanism, which beta blockers are implicated, how common the problem is, and what steps to take if you are affected.

Can Beta Blockers Cause Hair Loss?

Yes — beta blockers can cause hair loss by prematurely pushing follicles into the telogen (resting) phase, producing diffuse shedding known as telogen effluvium, as listed in several UK SmPCs.

Not sure if this is normal? Chat with one of our pharmacists →

Beta blockers are a widely prescribed class of medicines used to manage a range of conditions, including high blood pressure (hypertension), angina, heart failure, arrhythmias, and anxiety. They work by blocking the effects of adrenaline on beta-adrenergic receptors, thereby slowing the heart rate, reducing blood pressure, and decreasing the workload on the heart.

Hair loss — medically termed alopecia — is listed as a recognised, albeit uncommon, side effect of some beta blockers in their UK Summary of Product Characteristics (SmPC), as held on the MHRA/Electronic Medicines Compendium (EMC) database. The mechanism is not fully understood, but it is thought that beta blockers may interfere with the normal hair growth cycle. Hair follicles pass through distinct phases: anagen (growth), catagen (transition), and telogen (resting/shedding). Beta blockers are believed to prematurely push hair follicles into the telogen phase, resulting in a condition known as telogen effluvium — a diffuse, temporary form of hair shedding that typically becomes apparent two to four months after a triggering event or medication change. This mechanism is recognised in primary care dermatology guidance, including that of the Primary Care Dermatology Society (PCDS).

It is important to note that not everyone taking beta blockers will experience hair loss, and for many patients the cardiovascular or other clinical benefits of the medication far outweigh this potential side effect. Individual responses can vary considerably, and the presence of hair loss as a listed adverse effect differs between specific agents and their respective SmPCs.

How Common Is Hair Loss as a Side Effect?

Hair loss from beta blockers is uncommon; most UK SmPCs classify it as 'rare', 'very rare', or 'not known', and the true prevalence is likely underreported due to delayed onset and under-recognition.

Hair loss associated with beta blocker use is generally considered uncommon. The reported frequency varies between individual medicines: some UK SmPCs classify alopecia as 'rare' (affecting fewer than 1 in 1,000 users) or 'very rare' (fewer than 1 in 10,000), whilst others list it with a frequency of 'not known' — meaning it cannot be estimated reliably from available data. Patients should check the patient information leaflet or SmPC for their specific medicine for the most accurate frequency wording.

The true prevalence may be underreported. Hair loss can be a sensitive and distressing symptom, and patients do not always associate it with their medication, particularly when shedding begins weeks or months after starting treatment. Spontaneous reporting to the MHRA's Yellow Card scheme — the UK's pharmacovigilance system — captures some cases, but under-reporting is a well-recognised limitation of such systems.

The degree of hair loss also varies. Some individuals notice only mild thinning or increased shedding when brushing or washing hair, whilst others may experience more noticeable diffuse hair loss across the scalp. In most cases of drug-induced telogen effluvium, hair regrowth begins once the causative agent is discontinued or the dose is adjusted, with regrowth commonly becoming evident within three to six months. It is worth noting, however, that if a coexisting condition such as androgenetic alopecia (pattern hair loss) is present, that element may persist independently of any medication change. Drug-induced telogen effluvium itself is generally considered reversible, which can be reassuring for patients concerned about long-term effects on their appearance.

Have questions about your medication? Our pharmacists are here to help →

Which Beta Blockers Are Associated With Hair Loss?

Alopecia is listed as an adverse reaction for propranolol, atenolol, bisoprolol, carvedilol, nebivolol, and metoprolol in UK prescribing information, though comparative risk data between agents are limited.

Not all beta blockers carry the same risk of hair loss, and direct comparative data are limited. The class includes both non-selective beta blockers (which block both beta-1 and beta-2 receptors) and cardioselective beta blockers (which primarily target beta-1 receptors in the heart). Alopecia has been reported with several agents across both groups, and the frequency listing in individual UK SmPCs varies — in many cases it is recorded as 'not known' rather than a precise figure.

Beta blockers for which alopecia is listed as an adverse reaction in UK prescribing information include:

• Propranolol — a non-selective beta blocker used for hypertension, anxiety, and migraine prevention

• Atenolol — a cardioselective agent widely prescribed in the UK

• Bisoprolol — a cardioselective beta blocker commonly used in heart failure and hypertension management, in line with NICE guidance (NG106)

• Carvedilol — a non-selective beta blocker with alpha-blocking properties, used in heart failure

• Nebivolol — used in heart failure and hypertension

• Metoprolol — a cardioselective agent; less commonly used in the UK than bisoprolol or carvedilol

Because frequency data are inconsistent across SmPCs and robust comparative studies are lacking, it is not possible to reliably rank these medicines by their relative risk of causing hair loss. Patients and clinicians should consult the relevant UK SmPC (available via the MHRA/EMC) for the specific agent in question.

It is also worth noting that topical beta blockers used in eye drops for glaucoma (such as timolol) can be systemically absorbed and have, in rare cases, been associated with hair thinning, as noted in the UK ophthalmic timolol SmPC. Patients using these preparations should be aware of this possibility, even though the systemic dose is considerably lower than with oral formulations.

Note: nadolol is not routinely used or widely marketed in the UK and has therefore been omitted from this list.

What to Do If You Notice Hair Thinning or Shedding

Do not stop your beta blocker abruptly; instead, keep a record of symptoms, check your patient information leaflet, report via the MHRA Yellow Card scheme, and speak to your pharmacist or GP.

If you begin to notice increased hair shedding, thinning across the scalp, or changes in hair texture whilst taking a beta blocker, it is important not to stop your medication abruptly. Suddenly discontinuing beta blockers can cause a rebound effect, including a rapid increase in heart rate, worsening of angina, or a rise in blood pressure — all of which can be clinically dangerous.

Instead, consider the following steps:

• Keep a record of when the hair loss started, how much hair you are losing, and any other symptoms you have noticed. This information will be helpful when speaking to your GP or pharmacist.

• Check the patient information leaflet that came with your medication. Hair loss may be listed under side effects, which can help confirm whether your medicine is a potential cause.

• Report the side effect via the MHRA's Yellow Card scheme (available at yellowcard.mhra.gov.uk), which helps regulators monitor the safety of medicines in real-world use.

• Speak to your pharmacist as a first step if you are unsure whether your hair loss is related to your medication. Pharmacists are well placed to advise on common drug side effects and can help you decide whether a GP appointment is warranted.

• Seek earlier GP review if you experience very rapid or extensive shedding, scalp pain, tenderness, or inflammation, or if the hair loss is accompanied by other systemic symptoms such as fatigue, feeling cold, or heavy periods — as these may suggest an underlying medical cause requiring prompt assessment.

In the meantime, gentle hair care practices — avoiding excessive heat styling, tight hairstyles, and harsh chemical treatments — may help minimise further breakage whilst the underlying cause is being investigated.

Further patient-facing information on beta blockers and hair loss is available on the NHS website.

Speaking to Your GP About Changing or Stopping Treatment

Your GP can review whether switching to an alternative beta blocker, adjusting the dose, or substituting a different drug class is appropriate, but any change must be made gradually under clinical supervision.

If hair loss is causing you significant distress or appears to be worsening, arranging an appointment with your GP is the appropriate next step. Your GP can review your current medication, assess the likelihood that the beta blocker is responsible, and discuss whether any changes to your treatment plan are appropriate.

In some cases, your GP may consider:

• Switching to an alternative beta blocker, if clinically suitable, based on whether alopecia is listed for the current agent and the availability of alternatives for your condition

• Adjusting the dose, where this is safe and appropriate, to see whether a lower dose reduces the side effect whilst maintaining therapeutic benefit

• Substituting a different class of medicine if beta blockers are not the only suitable option for your condition — for example, an ACE inhibitor, calcium channel blocker, or angiotensin receptor blocker, in line with NICE hypertension guidance (NG136)

For heart failure, NICE guidance (NG106) specifies that bisoprolol, carvedilol, or nebivolol are the recommended beta blockers. Any switch between agents or to a different drug class must be made gradually and under medical supervision, with the choice tailored to your specific condition — whether that is hypertension, heart failure, arrhythmia, or post-myocardial infarction management.

It is essential that any changes to beta blocker therapy are clinician-supervised. For conditions such as heart failure or post-myocardial infarction management, beta blockers may be a cornerstone of treatment, and the decision to alter therapy requires careful consideration of clinical risk versus the impact on quality of life.

Be open and honest with your GP about how the hair loss is affecting you emotionally and psychologically, as this is a valid and important part of the clinical picture. Further prescribing context is available in the BNF beta blockers monograph.

When Hair Loss May Have Another Underlying Cause

Hair loss has many causes — including thyroid disorders, iron deficiency, and androgenetic alopecia — and your GP should arrange baseline blood tests (FBC, ferritin, TSH) to identify or exclude these before attributing shedding to medication.

Whilst beta blockers can contribute to hair shedding, hair loss is a common symptom with many potential causes, and the medication may not always be solely responsible. A thorough assessment by your GP can help identify or exclude other contributing factors.

Common causes of hair loss that may coincide with — or be mistaken for — drug-induced alopecia include:

• Thyroid disorders — both hypothyroidism and hyperthyroidism can cause diffuse hair thinning; a simple blood test (TSH) can screen for these

• Iron deficiency — low ferritin levels are a well-recognised cause of telogen effluvium, particularly in women

• Androgenetic alopecia — the most common form of hair loss in both men and women, related to genetic and hormonal factors (see NICE CKS: Male- and female-pattern hair loss)

• Alopecia areata — an autoimmune condition causing patchy hair loss (see NICE CKS: Alopecia areata)

• Significant physical or emotional stress — illness, surgery, bereavement, or major life events can all trigger temporary hair shedding

Your GP will typically arrange baseline blood tests in line with UK primary care practice, including a full blood count (FBC), ferritin, and thyroid function tests (TSH). Vitamin D testing may be considered if there are specific risk factors for deficiency; routine testing for zinc or biotin is not standard first-line practice in UK primary care unless there is a clear clinical indication.

Seek prompt GP review if you notice any of the following, as these may indicate a scarring, inflammatory, or infective cause of hair loss requiring specialist assessment:

• Scalp redness, soreness, tenderness, or pustules

• Patchy hair loss with scaling or broken hairs (which may suggest tinea capitis)

• Rapidly progressive or extensive loss

• Diagnostic uncertainty after initial assessment

If the cause remains unclear or hair loss is severe, your GP may refer you to a dermatologist with a specialist interest in hair disorders. PCDS telogen effluvium guidance provides a useful framework for primary care assessment and referral decisions.

Drug-induced telogen effluvium is generally reversible once the triggering factor is addressed, with regrowth typically evident within several months. However, if coexisting androgenetic alopecia is present, that element may continue independently. Addressing all contributing factors — whether medication-related or otherwise — often leads to meaningful improvement over time.

Frequently Asked Questions